Lupus (SLE) trials in China
163 trials · From ClinicalTrials.gov, checked 10 Nov 2026. Ask the study team whether a trial fits you.
Phase 1RecruitingTrial-stage medicine
Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
- Where
- Hangzhou, Hefei
- Age
- 18 years and over
- People
- 12
- Run by
- Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT06892145Registry updated 2025-12-22
No phaseNot yet recruitingTrial-stage medicine
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
- Where
- Tianjin
- Age
- 18 years to 65 years
- People
- 24
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07212322Registry updated 2025-12-19
Phase 1/2RecruitingTrial-stage medicine
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
- Where
- Shanghai
- Age
- 18 years to 65 years
- People
- 40
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06182969Registry updated 2025-12-16
Early phase 1RecruitingTrial-stage medicine
Allogeneic UCB-derived CAR-T for SLE
- Where
- Chengdu, Yancheng
- Age
- 18 years to 75 years
- People
- 48
- Run by
- Chengdu Ucello Biotechnology Co., Ltd.
See details and how to joinNCT07274059Registry updated 2025-12-10
Early phase 1Not yet recruitingTrial-stage medicine
CD19/BCMA CAR-T for SLE
- Where
- Chengdu
- Age
- 18 years to 75 years
- People
- 24
- Run by
- Chengdu Ucello Biotechnology Co., Ltd.
See details and how to joinNCT07266337Registry updated 2025-12-05
Phase 2RecruitingTrial-stage medicine
A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis
- Where
- Nanjing
- Age
- 18 years to 70 years
- People
- 51
- Run by
- Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07229742Registry updated 2025-12-01
Phase 1RecruitingTrial-stage medicine
Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus
- Where
- Hangzhou
- Age
- 5 years and over
- People
- 6
- Run by
- Mao Jianhua
See details and how to joinNCT06789107Registry updated 2025-11-28
Phase 1/2RecruitingTrial-stage medicine
The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
- Where
- Beijing
- Age
- 18 years to 70 years
- People
- 198
- Run by
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
See details and how to joinNCT07185269Registry updated 2025-11-26
Phase 1RecruitingTrial-stage medicine
Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
- Where
- Wuhan
- Age
- 18 years to 60 years
- People
- 12
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07031713Registry updated 2025-11-24
Phase 2RecruitingResearch participation
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
- Where
- Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing, Shanghai, Wuhan, Xiamen, Xi’an, Yangzhou
- Age
- 18 years to 75 years
- People
- 24
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT07038382Registry updated 2025-11-18
Phase 1RecruitingTrial-stage medicine
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
- Where
- Hangzhou
- Age
- 5 years and over
- People
- 18
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07233642Registry updated 2025-11-18
Phase 1RecruitingTrial-stage medicine
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
- Where
- Tianjin
- Age
- 18 years and over
- People
- 12
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06941129Registry updated 2025-09-29
Phase 1RecruitingTrial-stage medicine
Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
- Where
- Taiyuan, Wuhan
- Age
- 18 years to 60 years
- People
- 25
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06400537Registry updated 2025-09-17
Early phase 1RecruitingTrial-stage medicine
Safety Study of CC312 in Autoimmune Disease Patients
- Where
- Tianjin
- Age
- 18 years and over
- People
- 18
- Run by
- CytoCares Inc
See details and how to joinNCT06888960Registry updated 2025-09-17
Phase 1RecruitingTrial-stage medicine
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
- Where
- Chengdu
- Age
- 18 years to 65 years
- People
- 32
- Run by
- CytoCares Inc
See details and how to joinNCT07177911Registry updated 2025-09-17
Early phase 1RecruitingTrial-stage medicine
An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 20
- Run by
- Shanghai Cell Therapy Group Co.,Ltd
See details and how to joinNCT07174843Registry updated 2025-09-16
No phaseRecruitingTrial-stage medicine
Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
- Where
- Hefei
- Age
- 18 years and over
- People
- 18
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07121777Registry updated 2025-08-13
Phase 1RecruitingTrial-stage medicine
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
- Where
- Beijing
- Age
- 18 years to 70 years
- People
- 12
- Run by
- Juventas Cell Therapy Ltd.
See details and how to joinNCT06826430Registry updated 2025-08-07
Phase 1RecruitingTrial-stage medicine
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 30
- Run by
- RenJi Hospital
See details and how to joinNCT06249438Registry updated 2025-07-25
No phaseNot yet recruitingTrial-stage medicine
A Study of CAR-T Cells in Subjects With Systemic Lupus Erythematosus
- Where
- Wuhan
- Age
- 18 years to 65 years
- People
- 24
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06900764Registry updated 2025-07-17
Phase 1RecruitingTrial-stage medicine
Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus
- Where
- Beijing
- Age
- 18 years to 65 years
- People
- 20
- Run by
- Chinese SLE Treatment And Research Group
See details and how to joinNCT06881290Registry updated 2025-07-10
No phaseRecruitingTrial-stage medicine
CAR-T Cells Therapy for Patients With Autoimmune Diseases
- Where
- Hefei
- Age
- 18 years and over
- People
- 18
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07052565Registry updated 2025-07-08
Phase 1/2RecruitingTrial-stage medicine
Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells
- Where
- Shenzhen
- Age
- 18 years to 65 years
- People
- 58
- Run by
- Shenzhen Beike Bio-Technology Co., Ltd.
See details and how to joinNCT07041801Registry updated 2025-06-27
Phase 1/2Not yet recruitingTrial-stage medicine
MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.
- Where
- Shanghai
- Age
- 18 years to 65 years
- People
- 12
- Run by
- Shanghai Changzheng Hospital
See details and how to joinNCT07000292Registry updated 2025-06-11
No phaseRecruitingResearch participation
Long-Term Outcomes in SLE at Peking University People's Hospital
- Where
- Beijing
- Age
- 18 years and over
- People
- 1,000
- Run by
- Peking University People's Hospital
See details and how to joinNCT07005479Registry updated 2025-06-05
All Lupus (SLE) trials and the map
This page is not medical advice. Talk to your doctor before contacting a trial.